Stymied on Nas­daq, Ap­ple Tree’s Brae­burn sinks an­oth­er short putt with late-stage im­plant

Brae­burn Phar­ma­ceu­ti­cals is not out to rev­o­lu­tion­ize ther­a­py for the neu­ro­log­i­cal and psy­chi­atric dis­eases it fo­cus­es on. The Prince­ton, NJ-based biotech has one ap­proved prod­uct for an im­plant that is de­signed to me­ter out a steady dose of buprenor­phine — a well known gener­ic — over 6 months for opi­oid ad­dic­tion. And now it’s in the process of tee­ing up a sim­i­lar FDA ap­pli­ca­tion for an­oth­er im­plant that could pro­vide a 6-month dose of risperi­done to schiz­o­phren­ics af­ter run­ning a small Phase II/III study with 50 pa­tients.

Endpoints News

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.